No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Higher risk of mortality during COVID-19 infection among patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib at COVID-19 diagnosis

byKathleen Lau

January 29, 2021

in StudyGraphics

RELATED REPORTS

Artificial intelligence accelerates drug discovery and reduces animal testing

Sanofi wins approval for first Bruton’s tyrosine kinase inhibitor in immune thrombocytopenia

Royalty financing deepens exposure to small cell lung cancer revenues

Dihydroartemisinin-piperaquine reduces children death or readmission with severe anemia

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

AI Roundup

Artificial intelligence accelerates drug discovery and reduces animal testing

September 12, 2025

Long-term dual antiplatelet therapy does not increase mortality risk

Hematology

Sanofi wins approval for first Bruton’s tyrosine kinase inhibitor in immune thrombocytopenia

September 9, 2025

Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

September 3, 2025

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind Jan 25, 2021

Majority of obese tenth-graders already obese by fifth grade

Time restricted eating effective as a modest weight loss strategy for obese adults

Prescription of antibiotics for acute respiratory infections increasing

Tocilizumab not superior to standard care in randomized controlled trial for severe COVID-19 patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result